PT  - JOURNAL ARTICLE
AU  - CHRISTIAN EICHLER
AU  - JERIA EFREMOVA
AU  - KLAUS BRUNNERT
AU  - CHRISTIAN M. KURBACHER
AU  - OLEG GLUZ
AU  - JULIAN PUPPE
AU  - MATHIAS WARM
TI  - A Head to Head Comparison Between SurgiMend® – Fetal Bovine Acellular Dermal Matrix and Tutomesh® – A Bovine Pericardium Collagen Membrane in Breast Reconstruction in 45 Cases
DP  - 2017 Jul 01
TA  - In Vivo
PG  - 677--682
VI  - 31
IP  - 4
4099  - http://iv.iiarjournals.org/content/31/4/677.short
4100  - http://iv.iiarjournals.org/content/31/4/677.full
SO  - In Vivo2017 Jul 01; 31
AB  - Background/Aim: The use of acellular dermal matrices (ADM) has become a widely used option in breast reconstruction. A great deal of literature is available, totaling over 3,200 ADM reconstructions. Head-to-head comparisons between SurgiMend® and Tutomesh® are not yet reported. These are the first comparative clinical data reported on the use of Tutomesh® in breast reconstruction. Postoperative complication rates and costs for these devices were evaluated. Patients and Methods: This is a retrospective analysis of a 2-year experience with both SurgiMend® - fetal bovine acellular dermal matrix and Tutomesh® - a bovine pericardium collagen membrane in breast reconstruction in 45 cases from 2014-2015. Results: Forty-five patients received a total of 45 implant-based reconstructions using SurgiMend® (18 cases; 40%) or Tutomesh® (27 cases; 60%). Gross complication rates were 27.8% for SurgiMend® and 37.0% for Tutomesh® including hematoma, postoperative skin irritation, infection, red breast syndrome and revision surgery. The most common complication was postoperative red breast syndrome. Severe complications requiring revision surgery did not differ significantly in patients treated with SurgiMend® (0 cases, 0%) compared to Tutomesh® (1 case, 3.7%). Conclusion: This retrospective analysis shows similar overall clinical complication rates for Tutomesh® and SurgiMend®. Severe complication rates are comparable to those reported in literature for both products. Although the retrospective nature of this work limits its clinical impact, it is possible to opt for the cheaper alternative (Tutomesh®).